Skip to main content
. Author manuscript; available in PMC: 2008 Feb 15.
Published in final edited form as: Int J Cancer. 2008 Feb 15;122(4):742–750. doi: 10.1002/ijc.23114

Figure 3.

Figure 3

FAAH and MGLL immunostaining in pancreatic cancer. Low (a, g), moderate (b, h) and strong (c, i) immunostaining for FAAH or MGLL in pancreatic cancer cells, respectively. (df and jl) Corresponding specificity controls pre-adsorbed with the respective blocking peptide.